Deep Intelligent Pharma Secures Nearly $50 Million in Series D Funding to Redefine Clinical Development with Biomimetic AI Brain

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

Traditional new drug development faces a "dual dilemma": not only are the cycles long and costs high, but nearly 40% of failures stem from flaws in clinical trial design or non-scientific factors during execution. What the industry urgently needs now is no longer simple "human resource outsourcing," but rather an "intelligent decision-making system" capable of precisely avoiding risks.

Deep Intelligent Pharma has broken the traditional CRO "headcount-piling" service model, redefining the value anchor of AI in the pharmaceutical field – it's not just about doing things faster, but doing them right.

"We don't define success rate as simply 'getting it done,' but rather 'getting it right,'" said Ms. Li Xing, Founder/CEO of Deep Intelligent Pharma. "Through AI intervention, we conduct full-dimensional 'commercial endpoint' simulations in the early clinical stages, eliminating execution noise and design flaws, and strive to push the asset success rate of drug development to its theoretical limit."

After years of accumulation, Deep Intelligent Pharma has built the industry's first "Human-Brain-like Multi-Agent Ecosystem (Synaptic Agent Ecosystem)" based on the principles of bionics. It has the following three significant characteristics and advantages:

●Cognitive Atomism：DIP breaks down complex clinical medical logic into more than 10,000 high-precision "atomized Agents." From "eligibility criteria verification" to "statistical endpoint simulation," each Agent functions like a top specialist doctor, performing its own duties while maintaining high synergy.

● Bionic Human Brain, Synaptic Arrangement and Self-Evolution:Based on the iteration of "dark data (Process Knowledge)" from tens of thousands of past projects, DIP's system has developed a "code-level reflection mechanism." When encountering an unfamiliar pipeline, the system can hypothesize, verify, and achieve logical consistency like a human expert, rather than simply retrieving data from a database.

●Extreme precision derived from the "zero tolerance" gene in the medical field:Inheriting the company's "zero tolerance" training gene in the medical field, DIP's AI delivery has achieved industrial-grade accuracy of 99.9%, solving the fatal pain point of general models prone to "hallucinations" in serious medical scenarios.

Currently, Deep Intelligent Pharma has built a full-chain product matrix including Protocol Agent (scheme design intelligent agent), data statistics, pharmacovigilance, and clinical operations, achieving an end-to-end closed loop from "literature research" to "regulatory submission," and demonstrating astonishing "dimensionality reduction strike" capabilities in real-world validation.

Taking the clinical trial protocol design of Immunorock, an innovative oral cancer vaccine company based in Kobe, Japan, as an example. Immunorock has initiated a clinical trial for a new triple immunotherapy drug for oral cancer and needs to quickly complete and submit the Phase I/IIa protocol to PMDA. Under the traditional model, protocol design often relies heavily on individual experts' experience, which can easily lead to execution difficulties due to insufficient consideration.

Deep Intelligent Pharma not only successfully completed the independent AI-driven automatic writing of clinical trial protocols in an extremely short time, but also simulated the entire process from patient screening to data statistics before actual enrollment using "digital twin" technology. This allowed for the early detection of logical flaws in the protocol that could lead to high dropout rates. This "simulate first, execute later" model helped Immunorock avoid potential compliance risks, significantly improving the success rate of the clinical trial while achieving "zero revisions" and obtaining one-time approval from Japan’s PMDA. Without relying on a CRO, this approach saved the team 90% of their time.

The Lead Investor of This Round of FinancingCao Xu, Partner of CDH BF"It shows that Deep Intelligent Pharma is not just presenting a single technical tool, but a reconstruction of the underlying logic of pharmaceutical R&D. The barrier they have built using 'atomicized Agents' has shown us the possibility of transforming the CRO industry from 'labor-intensive' to completely 'technology-intensive.' In the global race for AI implementation in healthcare, Deep Intelligent Pharma has already occupied a strategically valuable niche."

Zhang Chi, Chairman of Xinding Capital"It's not just that Deep Intelligent Pharma has created a user-friendly AI tool, but they have truly achieved a leap from 'point technology' to a 'systematic platform.' In the high-barrier, highly regulated industry of new drug development, they have built an extremely high competitive barrier through years of accumulated know-how and Agent technology. We are optimistic about the team’s ability to transform this deterministic delivery capability into universal infrastructure for the global pharmaceutical industry, representing the best paradigm for AI implementation in vertical scenarios."

Chen Ge, Executive Director of Index CapitalSaid: "The global AI wave is reshaping the underlying structure of innovative drug research and development. Drug discovery tools are constantly advancing, but the clinical stage, which fundamentally determines the R&D cycle and success rate, is essentially a highly complex knowledge and text engineering process. A large number of critical decisions depend on the systematic expression of text, semantics, and knowledge logic. Deep Intelligent Pharma is one of the very few teams globally that has successfully implemented an AI-native multi-agent system across the entire clinical pathway, significantly shortening the R&D cycle and increasing success rates. We are delighted to participate in this round of financing and highly recognize the long-term dedication of CEO Li Xing and the executive team to the deep cultivation and accumulation of text and knowledge logic in the innovative drug R&D process, as well as their forward-thinking construction of organizational models for the AI era. We look forward to continuing to support Deep Intelligent Pharma in accelerating the coverage of global R&D pipelines and growing into a key cornerstone of future clinical R&D infrastructure."

Deep Intelligent Pharma (DIP), established in 2017, is a technology company dedicated to reshaping the entire drug development process using artificial intelligence. The company brings together top AI scientists and experienced clinical experts from around the globe. Through its self-developed Agent clusters and cognitive operating systems, it provides full-stack intelligent solutions for pharmaceutical companies worldwide, from pre-clinical to post-marketing stages, with the aim of making new drug development more precise, efficient, and cost-effective.